ClinicalTrials.gg
CompletedNCT03055221TRUST-2Updated Jan 5, 2024Results posted

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

A Phase 4 interventional study of Intravenous Treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 11 years 7 months after the study started (first participant enrolled Jun 2005, registered Feb 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
27th of 44
20 · median 32
Started
2005
with 2 others
Phase 4
14 of 44
1 open now
Registered
31st of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 27th largest by enrollment, is one of 3 that started in 2005, is one of 14 in phase 4, and was the 31st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Remodulin
  • 6-Minute Walk Test
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who were enrolled in and completed Study RIV-PH-402 (TRUST-1)

Exclusion criteria

Exclusion Criteria:

  • Subjects who were unblinded for potential rescue therapy in Study RIV-PH-402 and were found to be allocated to the Remodulin treatment group were not eligible to participate in this study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Intravenous Treprostinil

    Intravenous treprostinil was supplied as 1 mg/mL.

    Drug: Intravenous Treprostinil

Interventions

  • Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.

    Also known as: Remodulin

06

What researchers measure

Primary outcomes

  1. Effect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD)

    The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living.

    Time frame: The 6MWD was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit

  2. Effect of Long-term Remodulin Therapy on the NYHA Functional Classification

    The NYHA functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment).

    Time frame: The NYHA functional classification was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit

  3. Effect of Long-term Remodulin Therapy on Subject Safety

    Safety was assessed by summarizing the number of subjects with at least 1 AE during the 12 weeks (or until premature termination).

    Time frame: Baseline to Week 12

07

Results

Posted Jul 28, 2017

Participant flow

Participant flow — Overall Study
MilestoneIntravenous Treprostinil
Started20
Completed0
Not completed20
Withdrew: Adverse event2
Withdrew: Withdrawal by subject4
Withdrew: Death6
Withdrew: Physician decision1
Withdrew: Study terminated by sponsor3
Withdrew: Lost to follow-up4

Outcome measures

PrimaryEffect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD)

The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living.

Time frame:
The 6MWD was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit
Reported as:
Mean · Meters
Effect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD)
MetersIntravenous Treprostinil
Effect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD)440.8 ± 108.6
PrimaryEffect of Long-term Remodulin Therapy on the NYHA Functional Classification

The NYHA functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment).

Time frame:
The NYHA functional classification was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit
Reported as:
Mean · Functional Class
Effect of Long-term Remodulin Therapy on the NYHA Functional Classification
Functional ClassIntravenous Treprostinil
Effect of Long-term Remodulin Therapy on the NYHA Functional Classification2.1 ± 0.6
PrimaryEffect of Long-term Remodulin Therapy on Subject Safety

Safety was assessed by summarizing the number of subjects with at least 1 AE during the 12 weeks (or until premature termination).

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Effect of Long-term Remodulin Therapy on Subject Safety
ParticipantsIntravenous Treprostinil
Effect of Long-term Remodulin Therapy on Subject Safety14

Adverse events

Collected over Baseline to each subject's last visit, assessed up to approximately 9 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Treprostinil6/16 (37.5%)14/16 (87.5%)14/16 (87.5%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventIntravenous Treprostinil
PyrexiaGeneral disorders5/16
Catheter site infectionInfections and infestations4/16
Device dislocationGeneral disorders3/16
Device-related infectionInfections and infestations3/16
BacteraemiaInfections and infestations2/16
Device-related sepsisInfections and infestations2/16
Pyogenic granulomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/16
SepsisInfections and infestations1/16
CoagulopathyBlood and lymphatic system disorders1/16
Cardiac failure acuteCardiac disorders1/16
Most frequent other events
Showing 10 of 34
Most frequent other events
EventIntravenous Treprostinil
Abdominal discomfortGastrointestinal disorders3/16
NauseaGastrointestinal disorders3/16
Catheter site painGeneral disorders3/16
CoughRespiratory, thoracic and mediastinal disorders3/16
DiarrhoeaGastrointestinal disorders2/16
VomitingGastrointestinal disorders2/16
Pain in extremityMusculoskeletal and connective tissue disorders2/16
Pain in jawMusculoskeletal and connective tissue disorders2/16
HeadacheNervous system disorders2/16
DyspneaRespiratory, thoracic and mediastinal disorders2/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intravenous Treprostinil
Mean30.1 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous Treprostinil
Female9
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intravenous Treprostinil
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intravenous Treprostinil
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Intravenous Treprostinil
India16
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2005 to primary completion in Feb 2014, 104 months.

Results were first posted in Jul 2017, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2017
First posted
Feb 16, 2017
StartActual
Jun 10, 2005
Primary completionActual
Feb 25, 2014
CompletionActual
Feb 25, 2014
Results first posted
Jul 28, 2017
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03055221
Responsible party
Sponsor
First posted
Feb 16, 2017
Start date
Jun 10, 2005
Primary completion
Feb 25, 2014
Completion
Feb 25, 2014
Results posted
Jul 28, 2017
Last update
Jan 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion